Document is current

Article History

Received: 6 December 2025

Accepted: 12 February 2026

First Online: 13 March 2026

Declarations

:

: University College London Research Ethics Committee approved this study as a low-risk application on 28 October 2024 at 15:15, reference number: AH/2024/52-6625/003, in accordance with the Declaration of Helsinki. Written informed consent to participate in the study was obtained from all participants.

: Not applicable.

: AJ reports honoraria from Amgen, AstraZeneca, BMS, Gilead, GSK, Guardant, Merck, MSD, Johnson & Johnson, Pfizer, Bayer and Roche, and meeting support from Roche, Johnson & Johnson, MSD and Pfizer outside the submitted work. AH reports personal fees from Celgene, AstraZeneca, BMS, GSK and AbbVie (advisory boards), the American Journal of Managed Care (speaking fee), Jazz and Genentech (consulting), and Real Chemistry (immediate family member employment) outside the submitted work. No other disclosures were reported.